Action Prothena - PRTA

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

5,6403

Prix Achat

5,68

Prix Vente

5,98

Volume échangé

3 572 545

5,64 Fourchette du Jour 6,05

4,32 Plage de 52 semaines 25,42

Cap du marché

303,6M

Clôture Veille

5,75

Ouverture

5,92

Dernière Transaction

5.97

Dernière heure de transaction

Volume financier

US$ 20 756 864

VWAP

5,8101

Volume moyen (3 m)

1 648 012

Actions en circulation

53 826 982

Rendement du Dividende

Ratio Cours sur Bénéfices

-2,52

Bénéfice par action (BPA)

-2,27

Chiffre d'affairess

135,16M

Bénéfice net

-122,31M

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product c... Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). Show more

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.prothena.com

Siège social

Dublin, Irl

Fondé

Prothena Corporation PLC est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker PRTA. Le dernier cours de clôture d'Prothena était de US$5,75. Au cours de la dernière année, les actions de Prothena ont été négociées dans une fourchette de prix de US$ 4,32 à US$ 25,42.

Prothena compte actuellement 53 826 982 actions en circulation. La capitalisation boursière d'Prothena est de US$309,51 million. Prothena a un ratio cours/bénéfice (ratio PE) de -2.52.

Flux global

Baissier

Prime nette

-1M

Calls / Puts

0,00%

Ach. / Vent.

100,00%

OTM / ITM

0,00%

Sweeps Ratio

50,00%

Form 8-K - Current report

Prothena Announces Corporate Restructuring

Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company has initiated an approximate 63% reduction in its workforce to...

Form 8-K - Current report

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Data from Phase IIb PADOVA study and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Birtamimab did not meet the primary endpoint of time to all-cause mortality or the secondary endpoints Birtamimab development will be...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.6503	13.0320641283	4.99	6.03	4.95	2782784	5.6697671	CS
4	-0.8097	-12.5534883721	6.45	6.615	4.32	2643130	5.03687385	CS
12	-7.3897	-56.7129700691	13.03	13.22	4.32	1648012	6.71539089	CS
26	-10.6597	-65.3969325153	16.3	16.665	4.32	1006885	8.43925479	CS
52	-13.8397	-71.045687885	19.48	25.42	4.32	749850	11.92024349	CS
156	-18.9997	-77.1091720779	24.64	79.65	4.32	639008	31.7715709	CS
260	-4.3297	-43.4272818455	9.97	79.749	4.32	537085	32.26411332	CS

PRTA - Frequently Asked Questions (FAQ)

What is the current Prothena share price?

The current share price of Prothena is US$ 5,6403

How many Prothena shares are in issue?

Prothena has 53 826 982 shares in issue

What is the market cap of Prothena?

The market capitalisation of Prothena is USD 309,51M

What is the 1 year trading range for Prothena share price?

Prothena has traded in the range of US$ 4,32 to US$ 25,42 during the past year

What is the PE ratio of Prothena?

The price to earnings ratio of Prothena is -2,52

What is the cash to sales ratio of Prothena?

The cash to sales ratio of Prothena is 2,28

What is the reporting currency for Prothena?

Prothena reports financial results in USD

What is the latest annual turnover for Prothena?

The latest annual turnover of Prothena is USD 135,16M

What is the latest annual profit for Prothena?

The latest annual profit of Prothena is USD -122,31M

What is the registered address of Prothena?

The registered address for Prothena is 77 SIR JOHN ROGERSON’S QUAY, BLOCK C, GRAND CANAL DOCKLANDS, DUBLIN, D02 VK60

What is the Prothena website address?

The website address for Prothena is www.prothena.com

Which industry sector does Prothena operate in?

Prothena operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
NXTTNext Technology Holding Inc	US$ 3,44 (158,65%)	13,84M
WHLRWheeler Real Estate Investment Trust Inc	US$ 7,15 (109,06%)	52,35M
CTORCitius Oncology Inc	US$ 2,63 (69,68%)	20,77M
LUCYInnovative Eyewear Inc	US$ 3,52 (54,39%)	111,21M
LGCLLucas GC Ltd	US$ 1,0407 (53,16%)	11,17M
NWGLNature Wood Group Ltd	US$ 1,71 (-69,63%)	3,99M
ICUSeaStar Medical Holding Corporation	US$ 0,351 (-64,05%)	21,9M
MBRXMoleculin Biotech Inc	US$ 0,259999 (-55,40%)	16,84M
RGCRegencell Bioscience Holdings Ltd	US$ 37,50 (-40,81%)	2,22M
CGTLCreative Global Technology Holdings Ltd	US$ 1,4399 (-36,57%)	6,71M
HCTIHealthcare Triangle Inc	US$ 0,0297 (12,08%)	583,72M
DFLIDragonfly Energy Holdings Corporation	US$ 0,245 (12,39%)	334,37M
GNLNGreenlane Holdings Inc	US$ 0,009 (-13,04%)	262,88M
NVDANVIDIA Corporation	US$ 143,85 (-1,12%)	242,95M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 12,359 (-0,09%)	193,97M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Prothena Corporation PLC (PRTA) Cours

Prothena Corporation PLC (PRTA)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Prothena Corporation PLC

Flux d'options Prothena (PRTA)

Flux global

Baissier

Prime nette

-1M

Calls / Puts

0,00%

Ach. / Vent.

100,00%

OTM / ITM

0,00%

Sweeps Ratio

50,00%

PRTA Dernières nouvelles

Form 8-K - Current report

Prothena Announces Corporate Restructuring

Form 8-K - Current report

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Form 8-K - Current report

Prothena Announces Corporate Restructuring

Form 8-K - Current report

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

PRTA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Connectez-vous

Supprimer les publicités